| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $42.9M | — | +47.5% |
| R&D Expense | $1.5M | — | +42.5% |
| SG&A Expense | $16.2M | — | +46.3% |
| Operating Income | -$4.9M | — | +75.7% |
| Income Tax | $0 | — | — |
| Net Income | -$21.7M | — | +0.1% |
| EPS (Basic) | -$0.09 | — | +0.0% |
| EPS (Diluted) | -$0.09 | — | +0.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $78.9M | -2.8% | +20.9% |
| Accounts Receivable | $9.7M | +16.0% | -17.1% |
| Inventory | $21.6M | +13.2% | +28.6% |
| Current Assets | $115.9M | -19.2% | +11.6% |
| Total Assets | $653.5M | -9.1% | -3.6% |
| Current Liabilities | $26.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$21.1M | — | +12.1% |
| Capital Expenditures | $8.9M | — | +52.1% |
| Investing Cash Flow | -$9.1M | — | +95.5% |
| Financing Cash Flow | -$7.8M | — | -107.5% |
| Free Cash Flow | -$30.0M | — | -0.4% |
| -47.3% |
| Long-term Debt | $166.8M | +1.2% | -0.2% |
| Total Liabilities | $198.8M | -19.8% | -2.1% |
| Stockholders' Equity | $447.7M | -4.0% | -4.7% |